Expert review of vaccines

01 17 October 2026

DOI 10.1080/14760584.2026.2748741

The socioeconomic value of adult respiratory vaccination in Australia: a benefit-cost analysis

Open DOI

Matthew Napier, Angus Macfarlane, Ellie Tunnicliffe et al.

02 14 October 2026

DOI 10.1080/14760584.2026.2746121

Virus-like particle vaccines: from antigen architecture to antigen presentation and adaptive immune responses

Open DOI

Zihan Zhang, Huiwen Zheng, Longding Liu

1. Vaccination is one of the most effective public health interventions against infectious diseases. By reproducing selected features of pathogen exposure, vaccines can establish durable protective...

03 5 October 2026

DOI 10.1080/14760584.2026.2739087

Cost-effectiveness analysis of pneumococcal conjugate vaccines, PCV21 vs PCV20, in adults aged ≥60 years in Germany

Open DOI

Muloongo Simuzingili, Peter P. Mueller, Lisa M. Oexle et al.

04 27 September 2026

DOI 10.1080/14760584.2026.2722004

Booster vaccination with an investigational Lyme disease vaccine in children, adolescents, and adults: a plain language summary

Open DOI

Laura Wagner, Marc Messier, James H. Stark et al.

05 23 September 2026

DOI 10.1080/14760584.2026.2736329

Differing influenza vaccine uptake and recommendation behavior among healthcare workers in primary health centers, secondary and tertiary hospitals, and schools in a metropolis of southern China

Open DOI

Dan’ER Lin, Xiangting Zhang, Junxian Hu et al.

1. Influenza remains a major global public health concern, contributing substantially to the burden of respiratory infectious diseases. According to estimates from the World Health Organization (WH...

06 22 September 2026

DOI 10.1080/14760584.2026.2736328

Global policy determinants of national human papillomavirus vaccine introductions in 2006–2025

Open DOI

Jiyeon Suh, Marc Brisson, Emily A. Burger et al.

1. Human papillomavirus (HPV) infection is a necessary cause of cervical cancer, the fourth most common cancer in women worldwide in 2022, with the vast majority of cases occurring in low- and midd...

07 17 September 2026

DOI 10.1080/14760584.2026.2735166

Association of mRNA SARS-CoV-2 vaccination with fatigue and functional recovery in patients with post-acute sequelae of COVID-19 (PASC)

Open DOI

Philipp Pries, Jan Fuge, Michele Scharbau et al.

1. In 2019, first cases of acute coronavirus disease 2019 (COVID-19) caused by an infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) occurred. Following the acute COVID-19,...

08 17 September 2026

DOI 10.1080/14760584.2026.2734669

Progress and challenges of biological reference standards for vaccine quality control and evaluation

Open DOI

Xuanxuan Zhang, Yiping Wang, Fan Gao et al.

09 16 September 2026

DOI 10.1080/14760584.2026.2732508

Global vaccine readiness: equity-by-design in pandemic preparedness and response

Open DOI

Mahan Ghafari, Oliver J. Watson, Stefan Dascalu et al.

1. The global response to pandemics critically hinges on the timely distribution and administration of vaccines. To date, the COVID-19 vaccine roll-out has been the fastest and most widespread in h...

10 12 September 2026

DOI 10.1080/14760584.2026.2725347

Clinical and economic impact of bivalent respiratory syncytial virus prefusion F (RSVpreF) vaccination in older adults: a cost-effectiveness analysis for Chile

Open DOI

Rafael Bolanos, Tomas Eduardo Abbott, Ali Shajarizadeh et al.

1. Respiratory syncytial virus (RSV) is a common respiratory pathogen that typically causes mild, cold-like symptoms such as cough, nasal congestion, fever, sneezing, and wheezing [1]. However, in ...